Capstone Investment Advisors
DYN icon

Capstone Investment Advisors’s Dyne Therapeutics DYN Stock Holding History

Capstone Investment Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$203K Sell
11,217
-1,483
-12% -$25.6K ﹤0.01% 1518
2025
Q4 		$248K Buy
+12,700
New +$241K ﹤0.01% 1433
2024
Q2 		– Sell
-20,248
Closed -$575K – 2180
2024
Q1 		$575K Buy
+20,248
New +$458K ﹤0.01% 1479

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Capstone Investment Advisors's DYN Position: Q1 2026 in Review

Capstone Investment Advisors reduced its Dyne Therapeutics (DYN) stake by 12% in Q1 2026, selling an estimated $25.6K and leaving 11,217 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #1518.

Capstone Investment Advisors first reported a position in DYN in Q1 2024 and has held it in 3 quarters since. The position peaked at $575K in Q1 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Capstone Investment Advisors held 11,217 shares of Dyne Therapeutics worth $203K as of Q1 2026.
  • Capstone Investment Advisors sold 1,483 Dyne Therapeutics shares in Q1 2026, an estimated $25.6K.
  • Dyne Therapeutics made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #1518 holding.
  • Capstone Investment Advisors first reported a position in Dyne Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Capstone Investment Advisors's Dyne Therapeutics position peaked at $575K in Q1 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.